The post Hyperliquid Strategies Inc. announces a $30M stock buyback program appeared on BitcoinEthereumNews.com. Hyperliquid Strategies Inc., a digital asset treasury company, has announced that its board approved a stock buyback of up to $30 million of the Company’s outstanding common stock, par value $0.01 per share.  The stock repurchase program will be in place for up to 12 months. The company states that repurchases will be made from time to time in open market transactions at prevailing market prices, at management’s discretion. Hyperliquid cites providing investors with access to HYPE as the initiative According to Hyperliquid, the actual timing, number, and value of shares repurchased under the program will be determined by management at its discretion. It will also depend on several factors, including the market price of HSI’s common stock, general market and economic conditions, and applicable legal requirements. Company CEO David Schamis stated that the repurchase is aimed at enhancing shareholder value and increasing the exposure of each share to Hyperliquid’s ecosystem native token HYPE through capital operations.  David Schamis stated, “We are fully committed to maximizing shareholder value through disciplined execution of our treasury strategy. Our primary objective is providing investors with efficient access to HYPE, the native token of the dominant Hyperliquid eco-system. We will use our cash to increase our shareholders’ per-share exposure to HYPE in the most efficient way possible.” However, the company cannot guarantee the final number of shares repurchased, and the repurchase program may be extended, suspended, or terminated at any time at the company’s discretion without further notice. Additionally, Hyperliquid Strategies Inc. is the core of the Hyperliquid ecosystem. Hyperion DeFi recently announced the receipt of a Kinetiq airdrop and a partnership with Native Markets. The company reports assert that these changes should make HYPE tokens more valuable and easier to trade. The company has also taken steps to expand its holdings, purchasing an… The post Hyperliquid Strategies Inc. announces a $30M stock buyback program appeared on BitcoinEthereumNews.com. Hyperliquid Strategies Inc., a digital asset treasury company, has announced that its board approved a stock buyback of up to $30 million of the Company’s outstanding common stock, par value $0.01 per share.  The stock repurchase program will be in place for up to 12 months. The company states that repurchases will be made from time to time in open market transactions at prevailing market prices, at management’s discretion. Hyperliquid cites providing investors with access to HYPE as the initiative According to Hyperliquid, the actual timing, number, and value of shares repurchased under the program will be determined by management at its discretion. It will also depend on several factors, including the market price of HSI’s common stock, general market and economic conditions, and applicable legal requirements. Company CEO David Schamis stated that the repurchase is aimed at enhancing shareholder value and increasing the exposure of each share to Hyperliquid’s ecosystem native token HYPE through capital operations.  David Schamis stated, “We are fully committed to maximizing shareholder value through disciplined execution of our treasury strategy. Our primary objective is providing investors with efficient access to HYPE, the native token of the dominant Hyperliquid eco-system. We will use our cash to increase our shareholders’ per-share exposure to HYPE in the most efficient way possible.” However, the company cannot guarantee the final number of shares repurchased, and the repurchase program may be extended, suspended, or terminated at any time at the company’s discretion without further notice. Additionally, Hyperliquid Strategies Inc. is the core of the Hyperliquid ecosystem. Hyperion DeFi recently announced the receipt of a Kinetiq airdrop and a partnership with Native Markets. The company reports assert that these changes should make HYPE tokens more valuable and easier to trade. The company has also taken steps to expand its holdings, purchasing an…

Hyperliquid Strategies Inc. announces a $30M stock buyback program

Hyperliquid Strategies Inc., a digital asset treasury company, has announced that its board approved a stock buyback of up to $30 million of the Company’s outstanding common stock, par value $0.01 per share. 

The stock repurchase program will be in place for up to 12 months. The company states that repurchases will be made from time to time in open market transactions at prevailing market prices, at management’s discretion.

Hyperliquid cites providing investors with access to HYPE as the initiative

According to Hyperliquid, the actual timing, number, and value of shares repurchased under the program will be determined by management at its discretion. It will also depend on several factors, including the market price of HSI’s common stock, general market and economic conditions, and applicable legal requirements.

Company CEO David Schamis stated that the repurchase is aimed at enhancing shareholder value and increasing the exposure of each share to Hyperliquid’s ecosystem native token HYPE through capital operations. 

David Schamis stated, “We are fully committed to maximizing shareholder value through disciplined execution of our treasury strategy. Our primary objective is providing investors with efficient access to HYPE, the native token of the dominant Hyperliquid eco-system. We will use our cash to increase our shareholders’ per-share exposure to HYPE in the most efficient way possible.”

However, the company cannot guarantee the final number of shares repurchased, and the repurchase program may be extended, suspended, or terminated at any time at the company’s discretion without further notice.

Additionally, Hyperliquid Strategies Inc. is the core of the Hyperliquid ecosystem. Hyperion DeFi recently announced the receipt of a Kinetiq airdrop and a partnership with Native Markets. The company reports assert that these changes should make HYPE tokens more valuable and easier to trade.

The company has also taken steps to expand its holdings, purchasing an additional 150,000 HYPE tokens. 

Hyperliquid Strategies Inc. holds 12 million HYPE tokens, equivalent to 1.20% of the total supply, and has $300 million in cash reserves. These resources enable the company to repurchase shares and boost HYPE exposure in a capital-efficient manner. However, the success of the HYPE token is not guaranteed. It depends on the current state of the market.

The HYPE token remains steady, with a slight surge of 0.67% in the last 24 hours, following a period of constant decline over the weekend. CoinGlass data showed that the drop triggered more than $11 million in liquidations.

The shift marks a reversal for a protocol that once controlled the on-chain perpetuals market. Earlier in the year, Hyperliquid dominated the decentralized perpetuals market with near-total authority. However, that edge is long gone. 

Hyperliquid’s market dominance.  Source: DeFiLlama

The protocol’s share of the perpetual market has dropped from a peak of nearly 70% to less than 20% due to the emergence of more aggressive rivals, such as Aster and Lighter.

In addition, HYPE has lost almost 30% of its value in the last 30 days, making it the worst-performing asset among the top 20 crypto coin by market cap. As a result, crypto traders have become significantly bearish on the token, suggesting that the token’s value could drop to as low as $10.

Ultimately, regulatory instability, macroeconomic factors, and market volatility could all impact HYPE’s performance. The token is trending at its weakest level since May. It is currently trading at $29.80.

If you’re reading this, you’re already ahead. Stay there with our newsletter.

Source: https://www.cryptopolitan.com/hyperliquid-strategies-inc-announces-a-30m-stock-buyback-program/

Market Opportunity
WorldAssets Logo
WorldAssets Price(INC)
$0.6912
$0.6912$0.6912
-5.32%
USD
WorldAssets (INC) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26